Curesponse News
5 articles
growth-positive
Curesponse Presents Positive Preliminary Clinical Results from a Multi-Center UK Study at the AACR Meeting in Orlando, Florida
Curesponse, a precision oncology company, presented preliminary clinical results from a UK Study at the AACR meeting. The study demonstrated the predictive power of their cResponse platform in determining patient response to cancer therapeutics. The results showed a 96.5% sensitivity and 90% specificity across various solid cancer types. Curesponse plans to make the technology available for cancer patients in the UK and EU in 2023, and in the USA in 2024. The cResponse platform combines next-generation sequencing with a functional assay to assess the response of cancerous tissue to different drugs. It is the first personalized cancer platform that offers an empirical test within 2 weeks from biopsy.
CustomersPartners
growth-positive
Curesponse Announces Clalit Health Services, Largest Israeli HMO, to Provide Commercial Coverage for the cResponse™ test
Curesponse, a precision oncology company, announces that Clalit HMO has decided to include cResponse in its Oncology Services package for premium supplementary insurance members. The cResponse platform combines next-generation sequencing with a functional assay to assess the response of cancerous tissue to different drugs and drug combinations. Clalit Health Services, the worlds second-largest HMO, will now offer the cResponse assay to its members, expanding access to the technology for millions of cancer patients. This decision is seen as a recognition of the benefits the cResponse platform offers oncologists and patients in personalized cancer treatment selection.
Customers
growth-positive
Curesponse shows applicability of next generation Immuno-oncology drugs in the pan-cancer cResponse system
Curesponse, a precision oncology start-up, presented results at the ESMO Immuno-Oncology Congress demonstrating the application of their cResponse platform for modeling and evaluating immune modulating drugs in cancer tissue. The platform combines next-generation sequencing with a functional assay to assess the response of cancerous tissue to different drugs and drug combinations. The data presented showed the activation of T-cells and recruitment of immune cells in colorectal, lung, and pancreatic cancer. The cResponse platform has been utilized by cancer researchers and pharmaceutical companies and will be offered to cancer patients in the UK, EU, and USA in the coming years. The company is collaborating with leading pharma partners and the test is CE marked and reimbursed by private payers in Israel.
CustomersPartners
growth-positive
Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform
Curesponse, a cancer precision medicine company, has secured an additional USD 8 million funding for its breakthrough precision oncology platform. The funding will be used to scale clinical studies and expand the companys international footprint. Curesponses platform, cResponse, accurately predicts a patients response to cancer treatment by combining rapid genomic sequencing with a 3D functional assay. The platform takes into account tumor-microenvironment interactions and cancer tissue architecture, providing critical and actionable information for clinicians and patients. Recent clinical studies have shown that Curesponses technology predicts the patients clinical response with high specificity and sensitivity. The company aims to meet the increasing demand for personalized treatment in the precision medicine market.
InvestmentExpand
https://www.prnewswire.com/news-releases/curesponse-secures-6m-series-a-for-breakthrough-precision-medicine-301071319.html
